Pafupifupi-khansa / chithandizo / mayesero azachipatala / matenda / zofewa-minofu-sarcoma / chithandizo

Chithandizo cha Zipatala Zoyeserera Matenda Ofewa Sarcoma

Mayesero azachipatala ndi maphunziro ofufuza omwe amakhudza anthu. Kuyesedwa kwamankhwala pamndandandawu ndi mankhwala ofewa a sarcoma. Mayesero onse pamndandanda amathandizidwa ndi NCI.

Zambiri za NCI zokhudzana ndi mayesero azachipatala zimafotokozera mitundu ndi magawo am'mayesero ndi momwe amachitikira. Mayesero azachipatala amayang'ana njira zatsopano zotetezera, kuzindikira, kapena kuchiza matenda. Mungafune kuganizira zokhala ndi gawo pakuyesedwa kwachipatala. Lankhulani ndi dokotala wanu kuti akuthandizeni kusankha ngati mukuyenera.

Erdafitinib pochiza odwala omwe ali ndi zotupa zobwezerezedwanso kapena zowonongera zotsogola, zosakhala za Hodgkin Lymphoma, kapena zovuta za Histiocytic zosintha ndi FGFR Mutations (A Pediatric MATCH Treatment Trial)

Gawo ili lachiwiri la Matenda a Matenda a MATCH amafufuza momwe erdafitinib imagwirira ntchito pochiza odwala omwe ali ndi zotupa zolimba, non-Hodgkin lymphoma, kapena matenda a histiocytic omwe afalikira m'malo ena mthupi ndipo abwerera kapena osayankha chithandizo ndi kusintha kwa FGFR. Erdafitinib ikhoza kuyimitsa kukula kwa maselo a khansa potseka ma enzyme ena ofunikira kuti maselo akule.

Malo: Malo 107

Tazemetostat pochiza odwala omwe ali ndi zotupa zobwezeretsanso kapena zobwezeretsa zotupa, Non-Hodgkin Lymphoma, kapena Matenda a Histiocytic omwe ali ndi EZH2, SMARCB1, kapena SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Gawo ili lachiwiri la Matenda a Matenda a MATCH amafufuza momwe tazemetostat imagwirira ntchito pochiza odwala omwe ali ndi zotupa zolimba, non-hodgkin lymphoma, kapena matenda a histiocytic omwe afalikira m'malo ena mthupi ndipo abwerera kapena osayankha chithandizo ndipo ali ndi EZH2, SMARCB1 , kapena kusintha kwa majini a SMARCA4. Tazemetostat ikhoza kuyimitsa kukula kwa zotupa potseka ma enzyme ena ofunikira kuti maselo akule.

Malo: malo 109

PI3K / mTOR Inhibitor LY3023414 pochiza Odwala omwe ali ndi zotupa zobwezerezedwanso kapena zosintha zotupa, Non-Hodgkin Lymphoma, kapena Matenda a Histiocytic okhala ndi TSC kapena PI3K / MTOR Mutations (A Pediatric MATCH Treatment Trial)

Gawo lachiwiri lachiyero cha Matenda a MATCH limafufuza momwe PI3K / mTOR inhibitor LY3023414 imagwirira ntchito pochiza odwala omwe ali ndi zotupa zolimba, non-Hodgkin lymphoma, kapena matenda a histiocytic okhala ndi kusintha kwa TSC kapena PI3K / MTOR komwe kwafalikira m'malo ena m'thupi (metastatic) ndi abwerera (kubwereza) kapena samayankha chithandizo (chotsutsa). PI3K / mTOR inhibitor LY3023414 ikhoza kuyimitsa kukula kwa maselo a khansa potseka ma enzyme ena ofunikira kuti maselo akule.

Malo: Malo 107

Palbociclib pochiza odwala omwe ali ndi zotupa zobwezerezedwanso kapena zotsitsimula Rb Positive Advanced Solors Tumors, Non-Hodgkin Lymphoma, kapena Matenda a Histiocytic Omwe Amasinthira Kusintha Kwa Maselo Achilengedwe (Kuyesa Kwa Matenda a Ana)

Gawo ili lachiwiri la Matenda a Matenda a MATCH amafufuza momwe palbociclib imagwirira ntchito pochiza odwala omwe ali ndi zotupa zolimba za Rb, non-Hodgkin lymphoma, kapena matenda a histiocytic omwe amachititsa kusintha (masinthidwe) amtundu wamaselo omwe afalikira m'malo ena mthupi ndipo abwera kubwerera kapena osayankha chithandizo. Palbociclib ikhoza kuyimitsa kukula kwa maselo a khansa poletsa ena mwa michere yofunikira pakukula kwamaselo.

Malo: 97 malo

Larotrectinib pochiza odwala omwe ali ndi zotupa zobwezerezedwanso kapena zowonongera zotsogola, zosakhala za Hodgkin Lymphoma, kapena zovuta za Histiocytic ndi NTRK Fusions (A Pediatric MATCH Treatment Trial)

Gawo ili lachiwiri la Matenda a Matenda a MATCH amafufuza momwe larotrectinib imagwirira ntchito pochiza odwala omwe ali ndi zotupa zolimba, non-Hodgkin lymphoma, kapena matenda a histiocytic omwe ali ndi mafinya a NTRK omwe afalikira m'malo ena mthupi ndipo abwerera kapena sakuyankha kuchipatala. Larotrectinib ikhoza kuyimitsa kukula kwa maselo a khansa poletsa ena mwa michere yofunikira pakukula kwamaselo.

Malo: malo 109

Cabozantinib-S-Malate Pochiza Odwala Achichepere Omwe Amapezekanso, Amatsutsa, kapena Sarcomas Omwe Akupezeka, Wilms Tumor, kapena Zotupa Zina Zambiri

Gawo lachiwiri lachigawochi limafufuza momwe cabozantinib-s-malate imagwirira ntchito pochiza odwala achichepere omwe ali ndi sarcomas, chotupa cha Wilms, kapena zotupa zina zosowa zomwe zabwerera, sizimayankha chithandizo, kapena zimapezeka kumene. Cabozantinib-s-malate amatha kuyimitsa kukula kwa zotupa mwa kulepheretsa michere ina yofunikira pakukula kwa chotupa komanso kukula kwa chotupa chamagazi.

Malo: 137 malo

Olaparib pochiza odwala omwe ali ndi zotupa zobwezerezedwanso kapena zotsitsimula zotsogola, zosakhala za Hodgkin Lymphoma, kapena Matenda a Histiocytic omwe ali ndi Zofooka mu Kuwonongeka Kwakuwonongeka kwa DNA (Matenda Owonetsera Matenda a Ana)

Gawo lachiwiri lachiyero cha Matenda a ANTHU limafufuza momwe olaparib imagwirira ntchito pochiza odwala omwe ali ndi zotupa zolimba, non-Hodgkin lymphoma, kapena matenda a histiocytic okhala ndi zolakwika mu deoxyribonucleic acid (DNA) zowononga majini omwe afalikira kumadera ena m'thupi (patsogolo) ndi abwerera (abwereranso) kapena samayankha chithandizo (chotsutsa). Olaparib ikhoza kuletsa kukula kwa maselo otupa poletsa ma enzyme ena ofunikira kuti maselo akule.

Malo: Malo 105

Vemurafenib pochiza odwala omwe ali ndi zotupa zobwezeretsanso kapena zobwezeretsa zotupa, Non-Hodgkin Lymphoma, kapena Matenda a Histiocytic omwe ali ndi BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Gawo ili lachiwiri la Pediatric MatCH MATCH limafufuza momwe vemurafenib imagwirira ntchito pochiza odwala omwe ali ndi zotupa zolimba, omwe si a Hodgkin lymphoma, kapena zovuta za histiocytic zosintha za BRAF V600 zomwe zafalikira m'malo ena mthupi ndipo zabwerera kapena sizikulabadira chithandizo. Vemurafenib itha kuyimitsa kukula kwa zotupa mwa kulepheretsa michere ina yofunikira pakukula kwamaselo.

Malo: Malo 106

Atezolizumab pochiza odwala omwe ali ndi kachilombo koyambitsa matenda opatsirana pogonana kamene kamatha kuchotsedwa ndi opaleshoni

Gawo ili lachiwiri limawunika momwe atezolizumab imagwirira ntchito pochiza odwala omwe ali ndi alveolar soft part sarcoma omwe sanalandire chithandizo, afalikira kuchokera pomwe adayamba kupita kumalo ena mthupi ndipo sangathe kuchotsedwa ndi opaleshoni. Immunotherapy yokhala ndi ma monoclonal antibodies, monga atezolizumab, imatha kuthandizira chitetezo chamthupi kulimbana ndi khansa, ndipo imatha kusokoneza kuthekera kwa maselo otupa kukula ndikufalikira.

Malo: malo 39

Nivolumab ndi Ipilimumab pochiza Odwala omwe ali ndi kachilombo ka HIV kamene kamabwereranso kapena kachilombo koyambitsa matenda a Hodgkin Lymphoma kapena zotupa zolimba zomwe zimatha kapena kuchotsedwa ndi opaleshoni

Gawo ili loyeserera limafufuza zoyipa ndi mankhwala abwino kwambiri a nivolumab akamaperekedwa ndi ipilimumab pochiza odwala omwe ali ndi kachilombo ka HIV (HODgkin lymphoma) yomwe yabwerera pambuyo poti yasintha kapena siyiyankha chithandizo, kapena zotupa zolimba zomwe zafalikira m'malo ena m'thupi kapena sizingachotsedwe ndi opaleshoni. Immunotherapy yokhala ndi ma monoclonal antibodies, monga ipilimumab ndi nivolumab, imatha kuthandizira chitetezo chamthupi kulimbana ndi khansa, ndipo imatha kusokoneza kuthekera kwa maselo otupa kukula ndikufalikira. Ipilimumab ndi mankhwala omwe amatsutsana ndi molekyulu yotchedwa cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 imayang'anira gawo lina la chitetezo chamthupi mwanu potseka. Nivolumab ndi mtundu wa antibody womwe umafotokoza za kufa kwa cell 1 (PD-1), puloteni yomwe imayambitsa kuwonongeka kwa maselo amthupi. Kupatsa ipilimumab ndi nivolumab kumatha kugwira ntchito bwino pochiza odwala omwe ali ndi kachilombo ka HIV komwe kumalumikizidwa ndi Hodgkin lymphoma kapena zotupa zolimba poyerekeza ndi ipilimumab yokhala ndi nivolumab yokha.

Malo: malo 28

MDM2 Inhibitor AMG-232 ndi Therapy radiation pochiza odwala omwe ali ndi minofu yofewa ya Sarcoma

Gawo ili Ib kuyesa kumawunika zoyipa za MDM2 inhibitor AMG-232 ndi chithandizo chama radiation pochiza odwala omwe ali ndi minofu yofewa ya sarcoma. MDM2 inhibitor AMG-232 itha kuyimitsa kukula kwa maselo a khansa potseka ma enzyme ena ofunikira kuti maselo akule. Kupatsa MDM2 inhibitor AMG-232 ndi mankhwala a radiation asanachite opareshoni kumatha kupangitsa chotupacho kukhala chocheperako ndikuchepetsa kuchuluka kwa minofu yofunikira yomwe imafunika kuchotsedwa.

Malo: malo 27

Nivolumab wokhala ndi Ipilimumab kapena wopanda Pochiza Odwala Achichepere Omwe Amakhala Ndi Zotupa Zaposachedwa Kapena Zotsitsimula kapena Sarcomas

Gawo ili la mayesero a I / II limafufuza zoyipa ndi mankhwala abwino kwambiri a nivolumab akapatsidwa ndi kapena alibe ipilimumab kuti awone momwe amagwirira ntchito pochiza odwala achichepere kapena zotupa zolimba zomwe zabwerera (zabwereza) kapena osayankha chithandizo ( Zotsutsa). Immunotherapy yokhala ndi ma monoclonal antibodies, monga nivolumab ndi ipilimumab, imatha kuthandizira chitetezo chamthupi kulimbana ndi khansa, ndipo imatha kusokoneza kuthekera kwa maselo otupa kukula ndikufalikira. Sizikudziwika ngati nivolumab imagwira ntchito bwino payokha kapena ndi ipilimumab pochiza odwala omwe ali ndi zotupa zobwerezabwereza kapena zotsutsa kapena sarcomas.

Malo: 24 malo

Selinexor mu Advanced Liposarcoma

Izi ndizosasinthika, zowoneka bwino, zakhungu ziwiri, zowongoleredwa ndi placebo, Gawo la 2-3 la odwala omwe amapezeka kuti ali ndi liposarcoma yopanda tanthauzo. Pafupifupi odwala 279 onse adzasankhidwa kuti akaphunzire zamankhwala (selinexor kapena placebo).

Malo: Malo 21

(VOYAGER) Kafukufuku wa Avapritinib vs Regorafenib mwa Odwala Omwe Ali Ndi Matenda Osasunthika Omwe Amawonekera kapena Metastatic GIST

Izi ndizotseguka, zosasinthika, Phase 3 yophunzira mwa odwala omwe ali ndi kachilombo kosasunthika komweko kapenanso kachilombo koyambitsa matenda (GIST) ya avapritinib (yomwe imadziwikanso kuti BLU-285) motsutsana ndi regorafenib mwa odwala omwe kale amathandizidwa ndi imatinib ndi 1 kapena 2 ma TKIs ena.

Malo: malo 14

Kafukufuku Wachigawo 1 cha EZH2 Inhibitor Tazemetostat mu Maphunziro a Ana Omwe Anabwereranso Kapena Osokoneza INI1-Negative Tumors kapena Synovial Sarcoma

Awa ndi Gawo I, lotseguka, kuchuluka kwa kuchuluka kwa kuchuluka kwa kuchuluka kwa maphunziro ndi kuchuluka kwa mkamwa wa BID wa tazemetostat. Ophunzira adzayesedwa kuti akhale oyenerera pasanathe masiku 14 kuchokera pa mlingo woyamba wa tazemetostat. Makina azithandizo adzakhala masiku 28. Kuyankha poyankha kumayesedwa pakatha masabata asanu ndi atatu azachipatala ndipo pambuyo pake masabata asanu ndi atatu aliwonse pakuphunzira. Phunziroli lili ndi magawo awiri: Kuwonjezeka kwa Mlingo ndi Kukula Kwa Mlingo. Kuchuluka kwa mlingo wa maphunziro omwe ali ndi zilonda zobwereranso / zotsatirazi: - Zotupa za Rhabdoid: - Atypical teratoid rhabdoid tumor (ATRT) - Malignant rhabdoid tumor (MRT) - Rhabdoid chotupa cha impso (RTK) - Zotupa zosankhidwa zokhala ndi ma rhabdoid - zotupa za INI1 :

Malo: malo 14

Adavosertib ndi Irinotecan Hydrochloride Pochiza Odwala Achichepere Omwe Amabwerera Kumbuyo Kapena Owonjezeka

Gawo ili la mayeso a I / II limafufuza zoyipa ndi mankhwala abwino kwambiri a adavosertib ndi irinotecan hydrochloride pochiza odwala achichepere omwe ali ndi zotupa zolimba zomwe zabwerera (kubwereranso) kapena zomwe sizinayankhe kuchipatala (refractory). Adavosertib ndi irinotecan hydrochloride zitha kuyimitsa kukula kwa zotupa potseka ma enzyme ena ofunikira kuti maselo akule.

Malo: malo 22

Kuyesedwa kwa Phase III kwa Anlotinib mu Metastatic kapena Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma ndi Synovial Sarcoma

Kafukufukuyu akuwunikira chitetezo ndi mphamvu ya AL3818 (anlotinib) hydrochloride pochiza metastatic kapena advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), ndi synovial sarcoma (SS). Onse omwe ali ndi ASPS alandila AL3818 yotseguka. Mwa omwe ali ndi LMS kapena SS, AL3818 ifanizidwa ndi IV dacarbazine. Awiri mwa atatu mwa omwe atenga nawo mbali alandila AL3818, gawo limodzi mwa atatu mwa ophunzirawo alandila IV dacarbazine.

Malo: malo 14

Nab-Paclitaxel ndi Gemcitabine Hydrochloride pochiza Achinyamata kapena Achichepere Achikulire ndi Osteosarcoma Yobwezeretsa kapena Yotsitsimula, Ewing Sarcoma, Rhabdomyosarcoma, kapena Soft Tissue Sarcoma

Gawo ili lachiwiri limawunika momwe nab-paclitaxel ndi gemcitabine hydrochloride imagwira ntchito pochiza achinyamata kapena achikulire omwe ali ndi osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, kapena minofu yofewa ya sarcoma yomwe yabwerera kapena siyiyankha chithandizo. Mankhwala omwe amagwiritsidwa ntchito mu chemotherapy, monga nab-paclitaxel ndi gemcitabine hydrochloride, amagwira ntchito m'njira zosiyanasiyana kuti achepetse kukula kwa maselo otupa, mwina popha ma cell, powalekanitsa kuti asagawike, kapena poletsa kufalikira.

Malo: malo 18

Olaparib ndi Temozolomide pochiza Odwala omwe ali ndi Advanced, Metastatic, kapena Unresectable Uterine Leiomyosarcoma

Gawo lachiwiri lachiyeso limaphunzira olaparib ndi temozolomide pochiza odwala omwe ali ndi uterine leiomyosarcoma (LMS) yomwe yafalikira m'malo ena mthupi (yotsogola kapena metastatic) kapena yomwe singachotsedwe ndi opareshoni (osasinthika). Olaparib ikhoza kuletsa kukula kwa maselo otupa poletsa ma enzyme ena ofunikira kuti maselo akule. Mankhwala omwe amagwiritsidwa ntchito mu chemotherapy, monga temozolomide, amagwira ntchito m'njira zosiyanasiyana kuti achepetse kukula kwa zotupa, mwina popha ma cell, powalekanitsa kuti asagawike, kapena poletsa kufalikira. Kupereka olaparib ndi temozolomide zitha kugwira ntchito bwino kuposa kupatsa mankhwala okha pochiza odwala LMS.

Malo: malo 12

Chitetezo, Kuleza Mtima ndi PK Phunziro la DCC-2618 mwa Odwala Okhala Ndi Zovuta Zapamwamba

Izi ndi gawo la 1, lotseguka, loyambirira-mwa-munthu (FIH) kuchuluka kwa kuchuluka kwa kuchuluka kwa mayeso opangidwa kuti athe kuyesa chitetezo, kulolerana, pharmacokinetics (PK), pharmacodynamics (PD) ndi zoyambirira antitumor zochitika za DCC-2618, zoyendetsedwa pakamwa (PO), mwa odwala achikulire omwe ali ndi vuto lowopsa. Kafukufukuyu ali ndi magawo awiri, gawo lokulitsa mlingo komanso gawo lokulitsa.

Malo: malo 12

Nelfinavir Mesylate pochiza Odwala omwe ali ndi Kaposi Sarcoma

Kuyesa koyeserera kumeneku kwa kafukufukuyu kumafufuza momwe nelfinavir mesylate imagwirira ntchito pochiza odwala omwe ali ndi Kaposi sarcoma. Nelfinavir mesylate ikhoza kuyimitsa kukula kwa zotupa mwa kulepheretsa michere ina yofunikira pakukula kwamaselo.

Malo: Malo 11

sEphB4-HSA pochiza Odwala omwe ali ndi Kaposi Sarcoma

Gawo ili lachiwiri lachiyeso limafufuza zophatikizika za EphB4-HSA fusion protein (sEphB4-HSA) pochiza odwala omwe ali ndi Kaposi sarcoma. Mapuloteni osakanikirana a EphB4-HSA amatha kulepheretsa kukula kwa mitsempha yamagazi yomwe imapereka magazi ku khansa, komanso kutetezeranso maselo a khansa kukula.

Malo: malo 10

Gawo Lachiwiri, Kafukufuku Wambiri wa EZH2 Inhibitor Tazemetostat mwa Anthu Akuluakulu Omwe Ali ndi zotupa za INI1-Negative kapena Syapsviated / Refractory Synovial Sarcoma

Iyi ndi gawo lachiwiri, multicenter, lotseguka, mkono umodzi, kafukufuku wamagulu awiri a tazemetostat 800 mg BID yoyendetsedwa pakamwa mosalekeza masiku 28. Kuunikira kwamaphunziro kuti atsimikizire kuyenera kwa phunziroli kudzachitika pasanathe masiku 21 kuchokera pa mlingo woyamba wa tazemetostat. Maphunziro oyenerera adzalembetsedwa mu chimodzi mwa zakumwa zisanu kutengera mtundu wa chotupa: - Cohort 1 (Yotsekedwa kuti alembetse): MRT, RTK, ATRT, kapena zotupa zosankhidwa ndi ma rhabdoid, kuphatikiza cell carcinoma ya ovary hypercalcemic mtundu [SCCOHT], nawonso wodziwika kuti chotupa chowopsa cha ovary [MRTO] - Cohort 2 (Yotseka kuti alembetse): Kubwezeretsanso kapena kutsutsa synovial sarcoma ndi SS18-SSX kukonzanso - Gulu 3 (Yotsekedwa kuti mulembetse): Zotupa zina zoyipa za INI1 kapena chotupa chilichonse cholimba cha EZH2 phindu la kusintha kwa ntchito (GOF), kuphatikiza:

Malo: malo 12

SARC024: Protocol ya Blanket Yophunzirira Oral Regorafenib mwa Odwala Omwe Ali Ndi Ma Sarcoma Subtypes

Ngakhale regorafenib idavomerezedwa kuti igwiritsidwe ntchito kwa odwala omwe anali ndi GIST yopita patsogolo ngakhale imatinib ndi / kapena sunitinib potengera gawo lachiwiri ndi gawo lachitatu, sanayesedwe mwadongosolo mwa odwala omwe ali ndi mitundu ina ya sarcoma. Popeza ntchito ya sorafenib, sunitinib ndi pazopanib m'matumba ofewa, komanso umboni wa sorafenib mu osteogenic sarcoma komanso mwina Ewing / Ewing-sarcoma, pali zitsanzo zoyeserera ma SMOKI (ma molekyulu ang'onoang'ono a kinase inhibitors) monga regorafenib mu sarcomas kupatula GIST. Zimadziwikanso kuti ma SMOKIs (ma molekyulu ang'onoang'ono a kinase inhibitors) monga regorafenib, sorafenib, pazopanib, ndi sunitinib ali ndi mapanelo a kinase omwe amalumikizana nthawi imodzi. Ngakhale sizofanana,

Location: 10 locations

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

The primary objective is to assess the safety and tolerability of Toripalimab in subjects with various advanced malignancies and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of Toripalimab, 2) evaluate antitumor activity of Toripalimab; 3) determine the immunogenicity of Toripalimab; 4) evaluate overall survival. The exploratory objectives are to: 1) evaluate biomarkers that may correlate with activity of Toripalimab, 2) evaluate pharmacodynamic effects of Toripalimab on its target receptor, programmed cell death 1 (PD-1), as well as effects on the immune system. 3) evaluate the utility of PD-L1 & additional exploratory markers as biomarkers that could aid in selection of appropriate subjects for TAB001 therapy, and 4) identification of additional biomarkers correlating with response to treatment with TAB001.

Malo: Malo 9